T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.07% |
| 2 | Healthcare | 18.73% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.39% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGR
1651
DELISTED
Avangrid, Inc.
AGR
| $1.22M | ﹤0.01% |
29,151
+4,066
| +16% | +$195K |
|
1652
First Financial Bancorp
FFBC
$3.61B
| $1.21M | ﹤0.01% |
57,559
+5,837
| +11% | +$127K |
|
1653
Crinetics Pharmaceuticals
CRNX
$8.98B
| $1.21M | ﹤0.01% |
61,635
+7,228
| +13% | +$147K |
|
|
FL
1654
DELISTED
Foot Locker
FL
| $1.21M | ﹤0.01% |
38,889
-13,361
| -26% | -$427K |
|
1655
LXP Industrial Trust
LXP
$3.57B
| $1.21M | ﹤0.01% |
26,425
+3,234
| +14% | +$168K |
|
1656
Yeti Holdings
YETI
$3.34B
| $1.21M | ﹤0.01% |
42,433
+1,668
| +4% | +$69.5K |
|
1657
Fidelity MSCI Health Care Index ETF
FHLC
$3.4B
| $1.21M | ﹤0.01% |
20,944
| – | – |
|
1658
La-Z-Boy
LZB
$1.66B
| $1.21M | ﹤0.01% |
53,382
+2,090
| +4% | +$55.5K |
|
1659
ABM Industries
ABM
$2.82B
| $1.2M | ﹤0.01% |
31,485
-954,608
| -97% | -$41.8M |
|
1660
Atlantic Union Bankshares
AUB
$6.12B
| $1.2M | ﹤0.01% |
39,449
+5,088
| +15% | +$171K |
|
1661
Peoples Bancorp
PEBO
$1.49B
| $1.2M | ﹤0.01% |
41,315
+15
| +0% | +$441 |
|
1662
IPG Photonics
IPGP
$3.62B
| $1.19M | ﹤0.01% |
14,153
+4,558
| +48% | +$433K |
|
1663
Boise Cascade
BCC
$2.9B
| $1.19M | ﹤0.01% |
20,057
+3,381
| +20% | +$218K |
|
|
COOP
1664
DELISTED
Mr. Cooper
COOP
| $1.19M | ﹤0.01% |
29,446
+5,235
| +22% | +$221K |
|
1665
Sensient Technologies
SXT
$5.55B
| $1.19M | ﹤0.01% |
17,130
+2,706
| +19% | +$218K |
|
|
RVNC
1666
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.19M | ﹤0.01% |
43,975
+5,643
| +15% | +$114K |
|
1667
World Kinect Corp
WKC
$1.86B
| $1.19M | ﹤0.01% |
50,526
+5,682
| +13% | +$141K |
|
1668
CNO Financial Group
CNO
$5.12B
| $1.18M | ﹤0.01% |
65,820
-32,469
| -33% | -$602K |
|
1669
Kosmos Energy
KOS
$1.54B
| $1.18M | ﹤0.01% |
228,662
+35,381
| +18% | +$214K |
|
1670
DNOW Inc
DNOW
$2.98B
| $1.18M | ﹤0.01% |
117,568
-4,644
| -4% | -$50.2K |
|
|
RCM
1671
DELISTED
R1 RCM Inc. Common Stock
RCM
| $1.18M | ﹤0.01% |
63,733
+13,639
| +27% | +$311K |
|
1672
Phillips Edison & Co
PECO
$5.22B
| $1.18M | ﹤0.01% |
41,937
+10,025
| +31% | +$330K |
|
1673
HUB Group
HUBG
$2.51B
| $1.18M | ﹤0.01% |
34,048
+2,394
| +8% | +$91.5K |
|
1674
Delek US
DK
$4.15B
| $1.17M | ﹤0.01% |
43,235
+25,918
| +150% | +$684K |
|
1675
Brink's
BCO
$4.7B
| $1.17M | ﹤0.01% |
24,188
-881,872
| -97% | -$49.1M |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.